Prebiotic fiber to prevent gut inflammation after transplant
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This early-phase study tests a prebiotic (galacto-oligosaccharide) to see if it can lower or prevent gut inflammation caused by acute graft-versus-host disease (acute GVHD) after a stem cell transplant. If you’re scheduled for an allogeneic transplant, participating may help researchers find safer ways to protect your gut.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are planning an allogeneic stem cell transplant (donor cells) for any illness
- You are between 18 and 80 years old
- You are well enough to do everyday activities (Karnofsky score over 70)
- You are not pregnant and not breastfeeding
- You do not have serious ongoing gut problems like malabsorption, short bowel, or bile-related diarrhea
- You are not having moderate-to-severe stomach or bowel symptoms at enrollment (Grade 2 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking probiotics made from your own and your donor's bacteria can help prevent or reduce gut problems (like diarrhea) after a stem cell transplant. It may help your intestines recover and feel better.
This study tests whether a fecal microbiota transplant (a procedure that puts healthy donor bacteria into your gut) combined with a dietary fiber supplement can help treat gut graft-versus-host disease, a common complication after a stem cell transplant. It may help reduce diarrhea and other gut symptoms.
This trial tests whether omega-3 fatty acids can help prevent acute graft-versus-host disease (aGVHD) in people receiving a stem cell transplant from a donor. Omega-3 may reduce inflammation and lower the chance of this serious complication.
This Phase 2 study tests an oral “fecal microbiotherapy” treatment given before and around an allogeneic (donor) stem-cell transplant to help prevent transplant-related complications. It may help by improving gut and immune function during the high-risk transplant period.
This trial studies a treatment made from donor gut microbes to help prevent a common complication after a transplant called acute graft-versus-host disease (aGVHD). It may help by improving the balance and variety of gut bacteria during recovery after haploidentical transplant.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
Hear when a new Acute GVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.